X-153790211-C-G
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PP3_ModerateBS2
The NM_004135.4(IDH3G):āc.217G>Cā(p.Val73Leu) variant causes a missense change. The variant allele was found at a frequency of 0.0000548 in 1,093,968 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 18 hemizygotes in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: not found (cov: 25)
Exomes š: 0.000055 ( 0 hom. 18 hem. )
Consequence
IDH3G
NM_004135.4 missense
NM_004135.4 missense
Scores
5
7
5
Clinical Significance
Conservation
PhyloP100: 5.87
Genes affected
IDH3G (HGNC:5386): (isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma) Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. NAD(+)-dependent isocitrate dehydrogenases catalyze the allosterically regulated rate-limiting step of the tricarboxylic acid cycle. Each isozyme is a heterotetramer that is composed of two alpha subunits, one beta subunit, and one gamma subunit. The protein encoded by this gene is the gamma subunit of one isozyme of NAD(+)-dependent isocitrate dehydrogenase. This gene is a candidate gene for periventricular heterotopia. Several alternatively spliced transcript variants of this gene have been described, but only some of their full length natures have been determined. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.846
BS2
High Hemizygotes in GnomAdExome4 at 18 gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
IDH3G | NM_004135.4 | c.217G>C | p.Val73Leu | missense_variant | 4/13 | ENST00000217901.10 | NP_004126.1 | |
IDH3G | NM_174869.3 | c.217G>C | p.Val73Leu | missense_variant | 4/12 | NP_777358.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
IDH3G | ENST00000217901.10 | c.217G>C | p.Val73Leu | missense_variant | 4/13 | 1 | NM_004135.4 | ENSP00000217901.5 |
Frequencies
GnomAD3 genomes Cov.: 25
GnomAD3 genomes
Cov.:
25
GnomAD3 exomes AF: 0.0000109 AC: 2AN: 183056Hom.: 0 AF XY: 0.0000296 AC XY: 2AN XY: 67678
GnomAD3 exomes
AF:
AC:
2
AN:
183056
Hom.:
AF XY:
AC XY:
2
AN XY:
67678
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000548 AC: 60AN: 1093968Hom.: 0 Cov.: 30 AF XY: 0.0000501 AC XY: 18AN XY: 359540
GnomAD4 exome
AF:
AC:
60
AN:
1093968
Hom.:
Cov.:
30
AF XY:
AC XY:
18
AN XY:
359540
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 25
GnomAD4 genome
Cov.:
25
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 23, 2024 | The c.217G>C (p.V73L) alteration is located in exon 4 (coding exon 4) of the IDH3G gene. This alteration results from a G to C substitution at nucleotide position 217, causing the valine (V) at amino acid position 73 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Uncertain
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Pathogenic
.;D;.;D;D;D
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D;.;D;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D;D;D;D
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;M;.;.;.;.
PrimateAI
Pathogenic
D
PROVEAN
Benign
N;N;N;N;.;N
REVEL
Uncertain
Sift
Benign
D;D;D;D;.;D
Sift4G
Uncertain
D;T;D;D;D;T
Polyphen
0.059
.;B;.;.;.;.
Vest4
MutPred
Loss of ubiquitination at K74 (P = 0.2432);Loss of ubiquitination at K74 (P = 0.2432);Loss of ubiquitination at K74 (P = 0.2432);.;.;.;
MVP
MPC
1.1
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at